298 related articles for article (PubMed ID: 15067693)
1. Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system.
Dannenfelser RM; He H; Joshi Y; Bateman S; Serajuddin AT
J Pharm Sci; 2004 May; 93(5):1165-75. PubMed ID: 15067693
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture.
Joshi HN; Tejwani RW; Davidovich M; Sahasrabudhe VP; Jemal M; Bathala MS; Varia SA; Serajuddin AT
Int J Pharm; 2004 Jan; 269(1):251-8. PubMed ID: 14698596
[TBL] [Abstract][Full Text] [Related]
3. Dissolution improvement of high drug-loaded solid dispersion.
Okonogi S; Puttipipatkhachorn S
AAPS PharmSciTech; 2006 Jun; 7(2):E52. PubMed ID: 16796369
[TBL] [Abstract][Full Text] [Related]
4. In situ intestinal permeability and in vivo oral bioavailability of celecoxib in supersaturating self-emulsifying drug delivery system.
Song WH; Yeom DW; Lee DH; Lee KM; Yoo HJ; Chae BR; Song SH; Choi YW
Arch Pharm Res; 2014 May; 37(5):626-35. PubMed ID: 23852645
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical characterization and in vivo evaluation of flurbiprofen-loaded solid dispersion without crystalline change.
Oh DH; Park YJ; Kang JH; Yong CS; Choi HG
Drug Deliv; 2011 Jan; 18(1):46-53. PubMed ID: 20726805
[TBL] [Abstract][Full Text] [Related]
6. Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68.
Chen Y; Zhang GG; Neilly J; Marsh K; Mawhinney D; Sanzgiri YD
Int J Pharm; 2004 Nov; 286(1-2):69-80. PubMed ID: 15501003
[TBL] [Abstract][Full Text] [Related]
7. Effect of bile on the oral absorption of halofantrine in polyethylene glycol 400 and polysorbate 80 formulations dosed to bile duct cannulated rats.
Tønsberg H; Holm R; Mu H; Boll JB; Jacobsen J; Müllertz A
J Pharm Pharmacol; 2011 Jun; 63(6):817-24. PubMed ID: 21585380
[TBL] [Abstract][Full Text] [Related]
8. Development of clinical dosage forms for a poorly water-soluble drug II: formulation and characterization of a novel solid microemulsion preconcentrate system for oral delivery of a poorly water-soluble drug.
Li P; Hynes SR; Haefele TF; Pudipeddi M; Royce AE; Serajuddin AT
J Pharm Sci; 2009 May; 98(5):1750-64. PubMed ID: 18781639
[TBL] [Abstract][Full Text] [Related]
9. Selection of oral bioavailability enhancing formulations during drug discovery.
Zheng W; Jain A; Papoutsakis D; Dannenfelser RM; Panicucci R; Garad S
Drug Dev Ind Pharm; 2012 Feb; 38(2):235-47. PubMed ID: 21851310
[TBL] [Abstract][Full Text] [Related]
10. Designing an ADME liquid formulation with matching exposures to an amorphous dosage form.
Xi H; Yang Z; Tatavarti A; Xu W; Fuerst J; Ormes J
Int J Pharm; 2019 Jan; 554():48-53. PubMed ID: 30236644
[TBL] [Abstract][Full Text] [Related]
11. Exploration of supersaturable lacidipine ternary amorphous solid dispersion for enhanced dissolution and in vivo absorption.
Guan J; Jin L; Liu Q; Xu H; Wu H; Zhang X; Mao S
Eur J Pharm Sci; 2019 Nov; 139():105043. PubMed ID: 31415903
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a revaprazan-loaded solid dispersion, solid SNEDDS and inclusion compound: Physicochemical characterisation and pharmacokinetics.
Park JH; Kim DS; Mustapha O; Yousaf AM; Kim JS; Kim DW; Yong CS; Youn YS; Oh KT; Lim SJ; Kim JO; Choi HG
Colloids Surf B Biointerfaces; 2018 Feb; 162():420-426. PubMed ID: 29248606
[TBL] [Abstract][Full Text] [Related]
13. Development of novel ibuprofen-loaded solid dispersion with improved bioavailability using aqueous solution.
Park YJ; Kwon R; Quan QZ; Oh DH; Kim JO; Hwang MR; Koo YB; Woo JS; Yong CS; Choi HG
Arch Pharm Res; 2009 May; 32(5):767-72. PubMed ID: 19471892
[TBL] [Abstract][Full Text] [Related]
14. Fast-dissolving microparticles fail to show improved oral bioavailability.
Wong SM; Kellaway IW; Murdan S
J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654
[TBL] [Abstract][Full Text] [Related]
15. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
[TBL] [Abstract][Full Text] [Related]
16. Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone.
Sek L; Boyd BJ; Charman WN; Porter CJ
J Pharm Pharmacol; 2006 Jun; 58(6):809-20. PubMed ID: 16734982
[TBL] [Abstract][Full Text] [Related]
17. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.
Yan YD; Sung JH; Kim KK; Kim DW; Kim JO; Lee BJ; Yong CS; Choi HG
Int J Pharm; 2012 Jan; 422(1-2):202-10. PubMed ID: 22085435
[TBL] [Abstract][Full Text] [Related]
18. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
19. Design and evaluation of oral nanoemulsion drug delivery system of mebudipine.
Khani S; Keyhanfar F; Amani A
Drug Deliv; 2016 Jul; 23(6):2035-43. PubMed ID: 26406153
[TBL] [Abstract][Full Text] [Related]
20. [Application research of hot-melt extrusion in preparation of solid dispersion].
Chen MW; Chen WR; Chen TK; Chen RE; Wang YT
Yao Xue Xue Bao; 2012 Feb; 47(2):163-7. PubMed ID: 22512025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
